1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/56036
Full metadata record
DC FieldValueLanguage
dc.creatorIsamara Simasde Oliveirapt_BR
dc.creatorPaulo Fernando Tormin Borges Crosarapt_BR
dc.creatorGeovanni Dantas Cassalipt_BR
dc.creatorDiego Carlos Dos Reispt_BR
dc.creatorDanilo Santana Rodriguespt_BR
dc.creatorFlavio Barbosa Nunespt_BR
dc.creatorRoberto Eustáquio Santos Guimarãespt_BR
dc.date.accessioned2023-07-10T19:30:15Z-
dc.date.available2023-07-10T19:30:15Z-
dc.date.issued2016-
dc.citation.volume7pt_BR
dc.citation.issue2pt_BR
dc.citation.spage55pt_BR
dc.citation.epage61pt_BR
dc.identifier.doihttps://doi.org/10.2500/ar.2016.7.0160pt_BR
dc.identifier.issn21526575pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/56036-
dc.description.resumoIntroduction: Macrolides used as immunomodulators are a promising tool for chronic inflammatory airway diseases.Eosinophilic nasal polyposis (ENP) is still considered a disease that is difficult to control with the currently standardized treatments.Objectives: To evaluate prolonged treatment with low-dose azithromycin for ENP based on clinical and histopathologic variables.Methods: The present investigation was a self-paired case study of 33 patients with ENP. A comparison was performed between patients before and after treatment with azithromycin for 8 weeks. The patients were subjected to clinical examinations,staging (three-dimensional imaging by endoscopy), application of the questionnaire, and biopsy of nasal polyps at the beginning and at the end of the treatment. Results: The treatment yielded a clinical improvement regarding the two variables studied: polyposis staging (69.7%) and questionnaire (57.6%). We did not find significant differences in the inflammatory pattern and in the percentage or absolute number of eosinophils per field between samples obtained before and after the treatment (p > 0.05). There was no difference between the answers obtained from groups with and without asthma and/or aspirin intolerance (p>0.3). The patients with advanced initial staging exhibited lower subjective improvement index and staging reduction (p> 0.031 and p > 0.012, respectively). Conclusion: Based on this study, azithromycin may be considered as another therapeutic option for ENP. However, further studies are necessary to define the real mechanism of action involved.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentICB - DEPARTAMENTO DE PATOLOGIApt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE OFTALMOLOGIA E OTORRINOLARINGOLOGIApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofTherapeutic Advances in Allergy and Rhinology-
dc.rightsAcesso Abertopt_BR
dc.subjectMacrolidespt_BR
dc.subjectNasal polypspt_BR
dc.subjectAzithromycinpt_BR
dc.subjectEosinophilspt_BR
dc.subject.otherMacrolídeospt_BR
dc.subject.otherPólipos nasaispt_BR
dc.subject.otherAzitromicinapt_BR
dc.subject.otherEosinófilospt_BR
dc.titleAzithromycin for the treatment of eosinophilic nasal polyposis: clinical and histologic analysispt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://journals.sagepub.com/doi/full/10.2500/ar.2016.7.0160?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.orgpt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Azithromycin for the treatment of eosinophilic nasal pdfa.pdf111.15 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.